Cryogenic equipment for biotech

01Overview and value chain#

Markers EC: US FDA 21 CFR Part 210/211 + EU GMP Annex 1 for cryopreserved biological material storage and chain-of-custody | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)

Cryogenic equipment maintains biological materials — cell and gene therapy products, cord blood, biospecimens, master and working cell banks — at temperatures cold enough to suspend biological activity, typically below -150°C using liquid nitrogen (LN2) vapor or liquid phase, or -80°C for ultra-low mechanical freezers. The category spans three distinct hardware classes: controlled-rate freezers that ramp temperature down at a programmed rate to protect cell viability during the freeze itself, isothermal or LN2-jacketed storage tanks that hold frozen product at stable temperature for long-duration storage, and cryogenic shipping systems (dry-vapor shippers) that maintain temperature during transport without the spill and pressure risks of liquid-phase LN2. A single cell or gene therapy product typically passes through all three equipment classes across its manufacturing-to-patient journey, with a validated chain-of-custody and temperature-excursion record required at every handoff.

The key directions of cryogenic equipment for biotech are:

1. Controlled-rate freezing: programmable freezers that ramp temperature down at a validated rate (commonly 1°C/minute) to minimize ice-crystal damage and preserve cell viability during the freeze step itself.
2. LN2-jacketed and isothermal storage tanks: long-duration storage vessels that hold frozen product at stable cryogenic temperature, ranging from small lab tanks to high-capacity biorepository installations.
3. Cryogenic shipping systems: dry-vapor shippers that absorb liquid nitrogen into a porous matrix, maintaining cryogenic temperature during transport without free liquid phase, the standard for cell and gene therapy distribution logistics.
4. Temperature-monitoring and chain-of-custody software: connected sensors and tracking platforms that log temperature continuously and flag excursions across every handoff from manufacturing through patient administration.

Sectoral value chain#

[Cell/gene therapy product, biospecimen] ──> [Controlled-rate freezing]
                                                        │
                                              (validated freeze curve)
                                                        │
                                                        ▼
[Patient/end-use site] <─── [Cryogenic shipping] <─── [LN2 storage tank / biorepository]

Value chain levels#

Cross-cutting technologies of the sector:

• Dry-vapor shipping technology: a porous absorbent matrix holds liquid nitrogen in place, maintaining cryogenic vapor-phase temperature during transport without the pressure and spill risk of free liquid nitrogen.
• Multi-probe temperature monitoring: controlled-rate freezers with multiple independent temperature probes validate that the freeze curve is uniform across the full sample load, not just at a single reference point.
• Connected chain-of-custody platforms: cloud-linked temperature loggers provide continuous, auditable temperature records across every handoff from manufacturing through patient administration, a requirement increasingly specified for cell and gene therapy distribution.

02US#

The US hosts the category’s leading cryogenic hardware manufacturers and the dominant cryogenic logistics provider serving the world’s largest cell and gene therapy manufacturing and clinical distribution base.

cryogenic storage hardware leadership, dry-vapor shipping logistics dominance#

• Chart Industries (MVE brand): the MVE 616 wide-neck cylindrical biological LN2 storage tank and the MVE HE series with CryoVerse Connect controller and automated fill/gas-bypass functions are distributed through biomedical equipment resellers, a widely specified biological LN2 storage standard.
• Custom Biogenic Systems: manufactures both controlled-rate freezers with multi-probe monitoring and isothermal LN2-jacketed freezers, covering the freeze and long-duration storage steps of the pipeline from a single vendor.
• Cryoport: the Cryoport Express and Cryomax cryogenic shipping systems are the reference dry-vapor shipping platforms for life-sciences supply chains, specifically positioned for cell and gene therapy distribution logistics.
• Worthington Industries (Taylor-Wharton brand): the Taylor-Wharton LABS and VHC cryo storage tank lines are widely distributed through laboratory and biomedical equipment resellers, a long-established cryogenic tank brand.

03CN#

No China-headquartered cryogenic equipment maker cleared this screening round with confirmed, on-domain evidence; demand is driven by China’s expanding cell and gene therapy manufacturing and biobanking base, currently served largely through global vendors’ regional distribution networks.

import- and distributor-served market, domestic cell/gene therapy build-out#

• Global vendor distribution: Chart Industries, Cryoport and other global cryogenic equipment and logistics providers maintain China distribution channels serving domestic cell and gene therapy manufacturing and biobanking.
• Domestic cell/gene therapy build-out: China’s growing cell and gene therapy manufacturing base is the main demand driver for cryogenic storage and shipping capacity, without a confirmed domestic cryogenic-equipment originator identified in this screen.
• Screening note: one candidate China-headquartered cryogenic equipment maker was probed and did not return confirming, on-domain evidence this round — not asserted as absent, only as unconfirmed.

04EU#

No EU-headquartered vendor cleared this screening round; the category is dominated by US-headquartered cryogenic hardware and logistics providers whose global platforms (Chart/MVE, Cryoport, Taylor-Wharton) are also the reference standard specified across European cell and gene therapy manufacturing.

global US brand specification, distributor-served European demand#

• Global brand specification: European cell and gene therapy manufacturers specify the same MVE, Custom Biogenic Systems, Cryoport and Taylor-Wharton equipment lines sold in the US market, distributed through European biomedical equipment channels.
• Screening note: the region-specific search did not surface a distinct EU-headquartered cryogenic equipment originator with confirmed evidence in this round — not asserted as absent, only as unconfirmed.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack layers programmable freeze-curve control, cryogenic storage engineering and dry-vapor shipping technology on a common temperature-monitoring and chain-of-custody backbone.

1. Programmable controlled-rate freezing:
   • Freezers ramp temperature down at a validated rate (commonly around 1°C/minute) to minimize ice-crystal formation and preserve cell viability during the freeze transition.
   • Multi-probe monitoring validates that the freeze curve is uniform across the full sample load rather than only at a single reference point, a requirement for GMP-documented cell therapy freezing.
2. LN2-jacketed and automated-fill storage tanks:
   • Isothermal, LN2-jacketed tank designs hold stored product at stable cryogenic temperature with minimized liquid-nitrogen consumption versus open liquid-phase storage.
   • Automated fill and gas-bypass controllers maintain tank LN2 level without manual intervention, reducing the risk of a temperature excursion from a missed refill.
3. Dry-vapor cryogenic shipping:
   • A porous absorbent matrix holds liquid nitrogen in place, maintaining cryogenic vapor-phase temperature during transport without the pressure and spill risk of free liquid-phase nitrogen.
   • Connected chain-of-custody platforms log continuous, auditable temperature data across every handoff from manufacturing through patient administration.

07Value chains and production pipelines#

Industrial pipeline of cryogenic biological material handling (21 CFR Part 210/211 / EU GMP Annex 1)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Controlled-rate freezing │ ───> │ 2. Cryogenic storage         │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Chain-of-custody tracking│ <─── │ 3. Cryogenic shipping        │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Receipt and thaw         │ ───> │ 6. GMP documentation        │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Controlled-rate freezing

A programmable freezer ramps the product’s temperature down at a validated rate, protecting cell viability during the transition from liquid to frozen state.

Stage 2: Cryogenic storage

LN2-jacketed or isothermal tanks hold the frozen product at stable cryogenic temperature for long-duration storage, continuously temperature-logged.

Stage 3: Cryogenic shipping

A dry-vapor shipper maintains cryogenic temperature during transport without free liquid-phase nitrogen, validated for the shipping duration.

Stage 4: Chain-of-custody tracking

Connected temperature sensors and tracking software log continuous data and flag any excursion at every handoff from manufacturing through patient administration.

Stage 5: Receipt and thaw

The end-use site receives and thaws the product under a validated protocol matched to its cryopreservation method.

Stage 6: GMP documentation

Temperature records, chain-of-custody logs and excursion reports are compiled against a validated protocol under 21 CFR Part 210/211 and EU GMP Annex 1 for regulatory release.